Fever and neutropenia clinical practice guidelines. Review uri icon

Overview

MeSH Major

  • Fever
  • Guidelines as Topic
  • Neoplasms
  • Neutropenia

abstract

  • Significant progress has been made in managing fever and neutropenia in patients with cancer. Although initial empiric antimicrobial treatment remains the foundation of therapy for such patients, improved diagnostic modalities, models of risk assessment, and an understanding of the various clinical situations in which infections occur have required that treatment approaches and options evolve. The development of broad-spectrum antibiotics with decreased toxicity has improved patient outcomes. Nevertheless, the increasing prevalence of antibiotic-resistant pathogens has challenged the clinician to use antimicrobial therapy wisely. Infection control should not rely exclusively on antimicrobial prophylaxis but, rather, should continue to incorporate standard infection control measures and demand careful handwashing by all health care professionals who come into contact with immunocompromised patients. Invasive fungal pathogens have increased and remain a major concern. Diagnostic and therapeutic modalities for fungal infections remain limited, but careful clinical investigation of new approaches will be needed to define the proper use of these probably expensive new therapeutic additions.

publication date

  • September 2004

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 19780251

Additional Document Info

start page

  • 390

end page

  • 432

volume

  • 2

number

  • 5